to be frank with you I am a share holder and I am scared. Roger's numbers for not needing any funding until the end of 2015 does not add up, even the 50 million cash by the end of last quarter does not add up. I expected a drop of 20-25million in cash not 31 million. Is it 6 million extra working capital, if so why, the sales of Zohydro is not growing fast enough to need additional working capital. So what is going on?
This is a tug of war between the shorts and longs...shorts did not take into account two factors 1) hydrocodone combinations will become schedule 2 drugs, 2) acquisition of highly efficacious drug for the pipeline.
can purdue buy zgnx so they could become a publicly traded company in case they need to raise funds to battle lawuits?
Selling, general and administrative $44,939. Why do you need 45 million per quarter to market this drug? All you should need is 4 regional sales guys and a few inside sales. This is insane.
I just saw this on Twitter, This is amazing...
none of this matter, the total stake that Zognex has in ER market is .23%, the total market is significantly larger, it is just the Zogneix sales team is worthless. They need to start working on express scripts and get them to cover the formulation.
There is nothing to pump, they will lose $20+M this quarter. The sales of Zohydro is not growing fast enough to stem the losses of having to have 200 sales and marketing personnel.
That is not a jump, a jump would be 1275 to 5000, like the JAMA article said they are not even 0.25% of the ER perscriptions.
According to the article Zogenix sales team is inept: In July 2014, Zohydro ER’s sixth month of marketing, there were 3588 outpatient retail prescriptions dispensed. This represents 0.23% of the 1.6 million ER/LA opioid analgesic prescriptions and 0.02% of the nearly 18 million prescriptions dispensed for all opioid analgesics during the month.
Once you change the t-cells genetically they are no longer host cells. We all know GVHD is deadly so eventually you will see patients dying with CAR-T and FDA will halt the trials and ask for a plan to address that and that may not even be addressable. Juno already experienced patients dying with their small trial and you likely will see this happen again with Juno's large trial, and these guys will also likely experience the same.